Major fetal abnormalities associated with positive screening tests for Smith‐Lemli‐Opitz syndrome (SLOS)
- 8 February 2007
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 27 (5) , 409-414
- https://doi.org/10.1002/pd.1699
Abstract
Objective: Determine the relationship between positive screening interpretations for Smith‐Lemli‐Opitz syndrome (SLOS) and other fetal abnormalities, to aid counseling and diagnostic activities.Methods: An SLOS screening algorithm was incorporated into California's second‐trimester screening program for Down syndrome and open neural tube defects (ONTDs). Between 2002 and 2004, 777 088 pregnant women were given an SLOS risk interpretation, using alpha‐fetoprotein (AFP), unconjugated estriol (uE3), and human chorionic gonadotrophin (hCG) measurements. Outcomes were obtained in 98.8% of screen‐positive pregnancies.Results: SLOS screen positives, alone or in combination with screen positives for other fetal disorders (Down syndrome, trisomy 18, ONTD), were associated with a high risk for fetal pathology. Type and frequency of chromosomal or anatomic abnormalities (or fetal death) varied according to screen‐positive combination. Among 2018 screen‐positive pregnancies, 644 fetal deaths were identified. Among the 1374 viable pregnancies, 519 were screen positive for SLOS alone; two SLOS cases and 51 other serious abnormalities were identified (14 aneuploidies; 37 anatomic). The remaining 855 were also screen positive for at least one other disorder; two SLOS cases and 327 other abnormalities were identified (180 aneuploidies; 157 anatomic).Conclusion: For screening programs implementing the SLOS algorithm, the present data may be useful for counseling and to guide diagnostic studies. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 11 references indexed in Scilit:
- Identifying Smith–Lemli–Opitz syndrome in conjunction with prenatal screening for Down syndromePrenatal Diagnosis, 2006
- Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndromeJournal of Medical Screening, 2002
- Investigation of the epidemiology and prenatal diagnosis of holoprosencephaly in the North of EnglandAmerican Journal of Obstetrics and Gynecology, 2001
- Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetusesAmerican Journal of Medical Genetics, 1999
- Pituitary dysfunction, morbidity and mortality with congenital midline malformation of the cerebrumEuropean Journal of Pediatrics, 1999
- Pituitary gland and sella turcica in human trisomy 18 fetusesAmerican Journal of Medical Genetics, 1998
- Undetectable maternal serum unconjugated estriol levels in the second trimester: Risk of perinatal complications associated with placental sulfatase deficiencyAmerican Journal of Obstetrics and Gynecology, 1997
- Risk‐based prenatal screening for trisomy 18 using alpha‐fetoprotein, unconjugated oestriol and human chorionic gonadotropinPrenatal Diagnosis, 1995
- Second‐trimester levels of maternal serum unconjugated oestriol and human chorionic gonadotropin in pregnancies affected by fetal anencephaly and open spina bifidaPrenatal Diagnosis, 1990
- Maternal age specific rates for chromosome aberrations and factors influencing them: Report of a collaborative european study on 52 965 amniocentesesPrenatal Diagnosis, 1984